ClinicalTrials.gg
CompletedNCT00128102Updated Oct 26, 2020Results posted

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

A Phase 3 interventional study of Vorinostat and Placebo in Mesothelioma and Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
661
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen. The primary hypotheses are the following: (1) vorinostat improves overall survival (OS) compared to placebo (2) vorinostat is generally safe and well tolerated.

Read the detailed description

Treatment Extension Phase: Participants in this study will be eligible to enroll in an open-label treatment extension phase if they: a) were originally randomized to the vorinostat arm and have not experienced disease progression; b) were randomized to the placebo arm and meet the "Extension Phase Inclusion Criteria for Participants in the Placebo Arm" below; or c) were originally randomized to the vorinostat arm and discontinued study therapy for reasons other than progression and the investigator believes that it is in the participant's best interest to resume vorinostat treatment.

As specified by the protocol, based on planned extension phase inclusion criteria and pre-specified primary outcome analyses requirements, the extension phase of this study was not conducted.

02

Conditions studied

  • Mesothelioma
  • Lung Cancer

Keywords

  • Advanced malignant pleural mesothelioma
03

In context

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 60 are open to participants now.

This study's enrollment of 661 is above the median of 48 across 250 interventional studies indexed under Mesothelioma.

Browse Mesothelioma studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older with confirmed diagnosis of malignant pleural mesothelioma
  • In countries where pemetrexed is an approved mesothelioma treatment, the participant's disease has progressed or following treatment with at least one prior chemotherapy regimen with pemetrexed and either cisplatin or carboplatin OR in countries where pemetrexed is not approved for mesothelioma, the participant's disease has progressed or relapsed following treatment with at least one prior chemotherapy regimen OR pemetrexed is not the preferred therapy for the participant and the participant's disease has progressed or relapsed following treatment with at least one prior chemotherapy regimen
  • Received no more than 2 prior systemic therapy regimens
  • performance scale status of ≥70
  • Has adequate bone marrow, liver, and kidney function and adequate coagulation (per prespecified laboratory values)

Extension Phase Inclusion Criteria:

  • Participants who are receiving treatment with vorinostat and have not experienced progression of mesothelioma
  • Randomized to the placebo arm and: 1) have a Karnofsky performance scale status of ≥70; and 2) have adequate bone marrow, liver, and kidney function and adequate coagulation (per prespecified laboratory values)
  • Randomized to vorinostat and have discontinued study therapy for reasons other than progression of mesothelioma, if the investigator is of the opinion that the potential benefit outweighs potential risks associated with using vorinostat

Exclusion criteria

Exclusion Criteria:

  • Has an active infection for which they received treatment with intravenous antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drug.
  • Has a "currently active" second ; a malignancy is not considered "currently active" if participants have completed therapy for the second malignancy and are disease free from prior malignancies for >5 years
  • Has uncontrolled
  • Has a known (HIV) infection or HIV-related malignancy
  • Is pregnant or breast feeding
  • Has a history of gastrointestinal surgery or other procedures that might interfere with the absorption or swallowing of the study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
661 participants (actual)

Study arms

  • Experimental
    Vorinostat

    Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.

    Drug: Vorinostat

  • Placebo comparator
    Placebo

    Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.

    Drug: Placebo

Interventions

  • Vorinostat 100 mg oral capsules

    Also known as: MK-0683, Zolinza

  • DrugPlacebo

    Vorinostat-matching placebo oral capsules

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of final analysis were censored at the date of the last follow up. The final analysis for OS was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. OS analysis is reported here for all randomized participants.

    Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

  2. Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

    An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. Reporting of AEs per NCI CTCAE is based on 5 grades of severity; Grade 1 (mild; no treatment needed), Grade 2 (moderate; minimal treatment needed), Grade 3 (severe, not life threatening; hospitalization needed), Grade 4 (life threatening; urgent treatment needed) and Grade 5 (death).The final analysis for Grade 3 or 4 AEs was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who experienced Grade 3/4 AEs per NCI CTCAE is reported here for all randomized participants who received ≥1 dose of study treatment.

    Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

  3. Number of Participants Who Experienced an AE

    An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. The final analysis for participants who experienced an AE was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who experienced an AE is reported here for all randomized participants who received ≥1 dose of study treatment.

    Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

  4. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. The final analysis for participants who discontinued study treatment due to an AE was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who discontinued study treatment due to an AE is reported here for all randomized participants who received ≥1 dose of study treatment. As specified by the protocol, participants who discontinued study treatment due to an AE remained on study until investigator notification to discontinue.

    Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) per meso-modified-Response Evaluation Criteria in Solid Tumors (Meso-modified RECIST) based on independent radiology review or death due to any cause, whichever occurred first. Meso-modified RECIST was created and validated for disease measurement in pleural mesothelioma. Per meso-modified RECIST, PD was defined as ≥20% increase in the total tumor measurement over the nadir measurement or the appearance of ≥1 new lesions. The final analysis for PFS per Meso-modified RECIST by independent radiology review was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. PFS analysis per Meso-modified RECIST by independent radiology review is reported here for all randomized participants.

    Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants in the analysis population who had a complete response (CR: disappearance of all target lesions with no evidence of tumor elsewhere) or a partial response (PR: ≥30% reduction in the total tumor measurement) per Meso-modified RECIST based on independent radiology review. Meso-modified RECIST was created and validated for disease measurement in pleural mesothelioma. The final analysis for ORR per Meso-modified RECIST by independent radiology review was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol percentage of participants who had a CR or a PR per Meso-modified RECIST by independent radiology review is reported here as the ORR for all randomized participants who had valid baseline data for ORR analysis available.

    Time frame: Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)

  3. Percent Change From Baseline in Lung Cancer Symptom Scale, Modified for Mesothelioma (LCSS-Meso) Dyspnea Score at Week 12

    LCSS-Meso provides participant-reported outcome measures of symptom burden and quality of life. LCSS-Meso includes the disease-related item dyspnea or shortness of breath. The LCSS-Meso item dyspnea is measured on a visual analog scale (VAS) using 100 mm and assigned an individual score based on symptom intensity. Dyspnea VAS score ranges from 0 mm (lowest; no dyspnea) to 100 mm (highest; worst dyspnea). Higher scores indicate dyspnea worsening. Baseline measurement was taken before treatment initiation. Per protocol percent change in the LCSS-Meso dyspnea score from baseline to Week 12 post treatment initiation (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100)\] is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for the LCSS-Meso dyspnea score available.

    Time frame: Baseline, Week 12

  4. Percentage of Participants With ≥50% Change Together With a >10 mm Change From Baseline in the LCSS-Meso Dyspnea Score at Week 12

    LCSS-Meso provides participant-reported outcome measures of symptom burden and quality of life. LCSS-Meso includes the disease-related item dyspnea or shortness of breath. The LCSS-Meso item dyspnea is measured on a visual analog scale (VAS) using 100 mm and assigned an individual score based on symptom intensity. Dyspnea VAS score ranges from 0 mm (lowest; no dyspnea) to 100 mm (highest; worst dyspnea). Higher scores indicate dyspnea worsening. Baseline measurement was taken before treatment initiation. Per protocol percentage of participants with ≥50% change (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100) and \>10 mm absolute change in LCSS-Meso dyspnea score from baseline to Week 12 post treatment initiation is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for the LCSS-Meso dyspnea score available.

    Time frame: Baseline, Week 12

  5. Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 12

    Pulmonary function test was conducted using a spirometer for assessment of FVC. FVC is the volume of air forcibly exhaled from the lungs after taking the deepest breath possible. Baseline measurement was taken before treatment initiation. Per protocol percent change in FVC from baseline to Week 12 post treatment initiation (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100)\] is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for FVC available.

    Time frame: Baseline, Week 12

  6. Percentage of Participants With ≥10% Change From Baseline in FVC at Week 12

    Pulmonary function test was conducted using a spirometer for assessment of FVC. FVC is the volume of air forcibly exhaled from the lungs after taking the deepest breath possible. Baseline measurement was taken before treatment initiation. Per protocol percentage of participants with ≥10% change (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100) in FVC from baseline to Week 12 post treatment initiation is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for FVC.

    Time frame: Baseline, Week 12

07

Results

Posted Oct 26, 2020

Participant flow

Participant flow — Overall Study
MilestoneVorinostatPlacebo
Started329332
Treated329329
Completed10
Not completed328332
Withdrew: Site discontinued36
Withdrew: Other01
Withdrew: Progressive disease255285
Withdrew: Adverse event3411
Withdrew: Death1213
Withdrew: Physician decision33
Withdrew: Withdrawal by subject1911
Withdrew: Protocol violation22

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of final analysis were censored at the date of the last follow up. The final analysis for OS was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. OS analysis is reported here for all randomized participants.

Time frame:
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Reported as:
Median · Weeks
Overall Survival (OS)
WeeksVorinostatPlacebo
Overall Survival (OS)30.7 (26.71 to 36.14)27.1 (23.14 to 31.86)
Statistical analysis
  • Vorinostat vs Placebo · Log Rank · p = 0.858 · Hazard ratio (hr): 0.98 · 95% CI 0.83 to 1.17
PrimaryNumber of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. Reporting of AEs per NCI CTCAE is based on 5 grades of severity; Grade 1 (mild; no treatment needed), Grade 2 (moderate; minimal treatment needed), Grade 3 (severe, not life threatening; hospitalization needed), Grade 4 (life threatening; urgent treatment needed) and Grade 5 (death).The final analysis for Grade 3 or 4 AEs was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who experienced Grade 3/4 AEs per NCI CTCAE is reported here for all randomized participants who received ≥1 dose of study treatment.

Time frame:
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
ParticipantsVorinostatPlacebo
Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)165146
PrimaryNumber of Participants Who Experienced an AE

An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. The final analysis for participants who experienced an AE was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who experienced an AE is reported here for all randomized participants who received ≥1 dose of study treatment.

Time frame:
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an AE
ParticipantsVorinostatPlacebo
Number of Participants Who Experienced an AE327311
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. The final analysis for participants who discontinued study treatment due to an AE was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol number of participants who discontinued study treatment due to an AE is reported here for all randomized participants who received ≥1 dose of study treatment. As specified by the protocol, participants who discontinued study treatment due to an AE remained on study until investigator notification to discontinue.

Time frame:
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsVorinostatPlacebo
Number of Participants Who Discontinued Study Treatment Due to an AE6049
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from randomization to the first documented progressive disease (PD) per meso-modified-Response Evaluation Criteria in Solid Tumors (Meso-modified RECIST) based on independent radiology review or death due to any cause, whichever occurred first. Meso-modified RECIST was created and validated for disease measurement in pleural mesothelioma. Per meso-modified RECIST, PD was defined as ≥20% increase in the total tumor measurement over the nadir measurement or the appearance of ≥1 new lesions. The final analysis for PFS per Meso-modified RECIST by independent radiology review was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. PFS analysis per Meso-modified RECIST by independent radiology review is reported here for all randomized participants.

Time frame:
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Reported as:
Median · Weeks
Progression Free Survival (PFS)
WeeksVorinostatPlacebo
Progression Free Survival (PFS)6.3 (6.1 to 7.1)6.1 (6.0 to 6.1)
Statistical analysis
  • Vorinostat vs Placebo · Likelihood Based Score Test · p = <0.001 · Hazard ratio (hr): 0.75 · 95% CI 0.63 to 0.88
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants in the analysis population who had a complete response (CR: disappearance of all target lesions with no evidence of tumor elsewhere) or a partial response (PR: ≥30% reduction in the total tumor measurement) per Meso-modified RECIST based on independent radiology review. Meso-modified RECIST was created and validated for disease measurement in pleural mesothelioma. The final analysis for ORR per Meso-modified RECIST by independent radiology review was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. Per protocol percentage of participants who had a CR or a PR per Meso-modified RECIST by independent radiology review is reported here as the ORR for all randomized participants who had valid baseline data for ORR analysis available.

Time frame:
Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsVorinostatPlacebo
Objective Response Rate (ORR)0.63 (0.08 to 2.25)0.31 (0.01 to 1.71)
Statistical analysis
  • Vorinostat vs Placebo · Fisher Exact · p = 0.621 · Difference in percentage: 0.3 · 95% CI -1.18 to 1.97
SecondaryPercent Change From Baseline in Lung Cancer Symptom Scale, Modified for Mesothelioma (LCSS-Meso) Dyspnea Score at Week 12

LCSS-Meso provides participant-reported outcome measures of symptom burden and quality of life. LCSS-Meso includes the disease-related item dyspnea or shortness of breath. The LCSS-Meso item dyspnea is measured on a visual analog scale (VAS) using 100 mm and assigned an individual score based on symptom intensity. Dyspnea VAS score ranges from 0 mm (lowest; no dyspnea) to 100 mm (highest; worst dyspnea). Higher scores indicate dyspnea worsening. Baseline measurement was taken before treatment initiation. Per protocol percent change in the LCSS-Meso dyspnea score from baseline to Week 12 post treatment initiation (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100)\] is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for the LCSS-Meso dyspnea score available.

Time frame:
Baseline, Week 12
Reported as:
Mean · Percent Change
Percent Change From Baseline in Lung Cancer Symptom Scale, Modified for Mesothelioma (LCSS-Meso) Dyspnea Score at Week 12
Percent ChangeVorinostatPlacebo
Percent Change From Baseline in Lung Cancer Symptom Scale, Modified for Mesothelioma (LCSS-Meso) Dyspnea Score at Week 12141.8 (72.9 to 210.8)174.7 (40.4 to 308.9)
Statistical analysis
  • Vorinostat vs Placebo · Longitudinal Model · p = 0.259 · Difference in percent change: -52.4 · 95% CI -143.5 to 38.6
SecondaryPercentage of Participants With ≥50% Change Together With a >10 mm Change From Baseline in the LCSS-Meso Dyspnea Score at Week 12

LCSS-Meso provides participant-reported outcome measures of symptom burden and quality of life. LCSS-Meso includes the disease-related item dyspnea or shortness of breath. The LCSS-Meso item dyspnea is measured on a visual analog scale (VAS) using 100 mm and assigned an individual score based on symptom intensity. Dyspnea VAS score ranges from 0 mm (lowest; no dyspnea) to 100 mm (highest; worst dyspnea). Higher scores indicate dyspnea worsening. Baseline measurement was taken before treatment initiation. Per protocol percentage of participants with ≥50% change (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100) and \>10 mm absolute change in LCSS-Meso dyspnea score from baseline to Week 12 post treatment initiation is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for the LCSS-Meso dyspnea score available.

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥50% Change Together With a >10 mm Change From Baseline in the LCSS-Meso Dyspnea Score at Week 12
Percentage of participantsVorinostatPlacebo
Percentage of Participants With ≥50% Change Together With a >10 mm Change From Baseline in the LCSS-Meso Dyspnea Score at Week 1215.05 (11.19 to 19.62)16.39 (12.38 to 21.08)
Statistical analysis
  • Vorinostat vs Placebo · Fisher Exact · p = 0.736 · Difference in percentage: -1.3 · 95% CI -7.20 to 4.53
SecondaryPercent Change From Baseline in Forced Vital Capacity (FVC) at Week 12

Pulmonary function test was conducted using a spirometer for assessment of FVC. FVC is the volume of air forcibly exhaled from the lungs after taking the deepest breath possible. Baseline measurement was taken before treatment initiation. Per protocol percent change in FVC from baseline to Week 12 post treatment initiation (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100)\] is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for FVC available.

Time frame:
Baseline, Week 12
Reported as:
Mean · Percent Change
Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 12
Percent ChangeVorinostatPlacebo
Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 12-6.0 (-9.82 to -2.09)-5.6 (-9.2 to -2.0)
Statistical analysis
  • Vorinostat vs Placebo · Longitudinal Model · p = 0.979 · Difference in percent change: -0.06 · 95% CI -4.61 to 4.49
SecondaryPercentage of Participants With ≥10% Change From Baseline in FVC at Week 12

Pulmonary function test was conducted using a spirometer for assessment of FVC. FVC is the volume of air forcibly exhaled from the lungs after taking the deepest breath possible. Baseline measurement was taken before treatment initiation. Per protocol percentage of participants with ≥10% change (percent change calculated: \[Week 12 - Baseline\]/Baseline\*100) in FVC from baseline to Week 12 post treatment initiation is reported here for all randomized participants who had a valid baseline and ≥1 post-baseline value for FVC.

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥10% Change From Baseline in FVC at Week 12
Percentage of participantsVorinostatPlacebo
Percentage of Participants With ≥10% Change From Baseline in FVC at Week 1224.76 (19.08 to 31.17)21.63 (16.24 to 27.86)
Statistical analysis
  • Vorinostat vs Placebo · Fisher Exact · p = 0.488 · Difference in percentage: 3.1 · 95% CI -4.97 to 11.17

Adverse events

Collected over Up to ~77 months (through database cut-off date of 21-November-2011). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat288/329 (87.5%)133/329 (40.4%)303/329 (92.1%)
Placebo284/332 (85.5%)131/329 (39.8%)281/329 (85.4%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventVorinostatPlacebo
Pleural mesothelioma malignant advancedNeoplasms benign, malignant and unspecified (incl cysts and polyps)50/32959/329
DyspnoeaRespiratory, thoracic and mediastinal disorders11/32925/329
PneumoniaInfections and infestations13/32910/329
NauseaGastrointestinal disorders12/3290/329
AnaemiaBlood and lymphatic system disorders10/3293/329
FatigueGeneral disorders8/3292/329
Accidental overdoseInjury, poisoning and procedural complications8/3290/329
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/3298/329
Atrial fibrillationCardiac disorders6/3293/329
VomitingGastrointestinal disorders6/3292/329
Most frequent other events
Showing 10 of 28
Most frequent other events
EventVorinostatPlacebo
NauseaGastrointestinal disorders189/329104/329
FatigueGeneral disorders153/329128/329
DiarrhoeaGastrointestinal disorders142/32958/329
Decreased appetiteMetabolism and nutrition disorders133/32985/329
VomitingGastrointestinal disorders131/32945/329
DyspnoeaRespiratory, thoracic and mediastinal disorders97/32997/329
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)59/32983/329
ConstipationGastrointestinal disorders80/32969/329
Weight decreasedInvestigations67/32926/329
CoughRespiratory, thoracic and mediastinal disorders59/32966/329

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VorinostatPlaceboTotal
Mean64.2 ± 9.564.4 ± 9.364.3 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)VorinostatPlaceboTotal
Female4662108
Male283270553
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Ohman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr;16(4):447-56. doi: 10.1016/S1470-2045(15)70056-2. Epub 2015 Mar 20. Erratum In: Lancet Oncol. 2015 May;16(5):e199. doi: 10.1016/S1470-2045(14)71115-5. PubMed 25800891 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2005 to primary completion in Jul 2011, 72 months.

Results were first posted in Oct 2020, 9 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2005
First posted
Aug 9, 2005
StartActual
Jun 30, 2005
Primary completionActual
Jul 15, 2011
CompletionActual
Nov 21, 2011
Results first posted
Oct 26, 2020
Last update
Oct 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00128102
Responsible party
Sponsor
First posted
Aug 9, 2005
Start date
Jun 30, 2005
Primary completion
Jul 15, 2011
Completion
Nov 21, 2011
Results posted
Oct 26, 2020
Last update
Oct 26, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion